Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Verapamil
Drug ID BADD_D02348
Description Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina,[L8791] and was the first calcium channel antagonist to be introduced into therapy in the early 1960s.[A188514] It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications.[L8791] Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.[A188435]
Indications and Usage For the treatment of hypertension, angina, and cluster headache prophylaxis.
Marketing Status Prescription; Discontinued
ATC Code C08DA01
DrugBank ID DB00661
KEGG ID D02356
MeSH ID D014700
PubChem ID 2520
TTD Drug ID D0R0FE
NDC Product Code 70966-0029
Synonyms Verapamil | Iproveratril | Cordilox | Dexverapamil | Verapamil Hydrochloride | Hydrochloride, Verapamil | Finoptin | Izoptin | Isoptine | Isoptin | Lekoptin | Calan | Falicard
Chemical Information
Molecular Formula C27H38N2O4
CAS Registry Number 52-53-9
SMILES CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
Sudden cardiac deathPotassium voltage-gated channel subfamily E member 1P15382Not Available9927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily H member 2Q12809T202519927398; 10810773; 10082151; 10408028
Sudden cardiac deathPotassium voltage-gated channel subfamily KQT member 1P51787T495269927398; 10810773; 10082151; 10408028
Sudden cardiac deathSodium channel protein type 5 subunit alphaQ14524T397169927398; 10810773; 10082151; 10408028
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Emotional distress19.04.02.008--Not Available
Muscle fatigue15.05.03.006--Not Available
Quadriparesis17.01.04.012--Not Available
Balance disorder17.02.02.007--Not Available
Contusion24.07.06.001; 15.03.01.008; 23.03.11.002; 12.01.06.001--
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Haemodynamic instability24.03.02.0060.000646%Not Available
Cardiac flutter02.03.02.012--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Depressive symptom19.15.02.003--Not Available
Pulseless electrical activity02.03.04.0200.000431%Not Available
Brugada syndrome02.03.01.0130.000431%Not Available
Hepatic enzyme increased13.03.01.019--Not Available
Prostate cancer21.04.02.002; 16.25.01.0010.000112%Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Inner ear disorder04.04.02.002--Not Available
Psychotic disorder19.03.01.002--
Treatment failure08.06.01.0170.000112%Not Available
Brain injury19.07.03.007; 17.11.01.0030.000112%Not Available
Acute kidney injury20.01.03.0160.001292%
Atrioventricular dissociation02.03.01.012--Not Available
Atrial thrombosis24.01.05.005; 02.01.01.0130.000646%Not Available
Vasoplegia syndrome24.06.03.011; 12.02.01.0100.001077%Not Available
Myocardial stunning24.04.04.024; 02.02.02.0210.000861%Not Available
The 6th Page    First    Pre   6    Total 6 Pages